Word: upjohn
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...four drugs currently available for U.S. prescription in the treatment of adult diabetes, three are sulfonylureas: tolbutamide (Upjohn's Orinase), chlorpropamide (Pfizer's Diabinese) and acetohexamide (Lilly's Dymelor). Drs. Weller and Linder emphasize that these sulfonylureas promote the release of insulin-at least in the early stages of treatment-and thus help to make fat. They recommend sulfonylureas for patients whose weight problems are not critical and for the few who are underweight. For the overweight, they prescribe phenformin (U.S. Vitamin Corp.'s DBI), which, they say, helps both to control appetite and to speed...
...through Brussels a faculty member barraged the students with questions. "Who recently introduced the lower bank rate in France?" A student's correct answer: "Valéry Giscard d'Estaing." "Why?" "To spur investment." At the International School of Brussels, U.S. executives of Ford, I.T.T., Monsanto and Upjohn got a grilling from the students: "Why are Germany's gold reserves going down when its economy is booming?" "What marketing research have you done in Europe on oral contraceptives?" In Paris, the Americans met Gaullist students to discuss the mysteries of the world's teen-agers...
...comes closer to the natural physiological hormone cycle. Mead, Johnson & Co. already has an application before FDA asking approval of sequential-therapy pills compounded of ingredients bought from British Drug Houses, Ltd. And Indianapolis' Eli Lilly & Co., working with Syntex, is on the same tack. Michigan's Upjohn Co. is preparing a pill it calls Provest, and Pennsylvania's Wyeth Laboratories are testing still another...
...Upjohn Co., Kalamazoo, Mich., $1,507,040; Warner-Lambert Pharmaceutical Co., Morris Plains, N.J., $1,500,000; Charles Pfizer & Co., Inc., N.Y.C., $1,500,000; Wyeth Laboratories, Radnor, Pa., $1,491,601; Sterling Drug Inc., N.Y.C., $1,407,076; McKesson & Robbins, Inc., N.Y.C., $1,398,301; Hoffman-La Roche Inc., Nutley, N.J., $1,131,841; Bristol-Myers Co., N.Y.C...
...must go through a complex, time-consuming procedure to get it off the market. Usually, in such cases, the drugmakers cooperate more or less voluntarily, since they have as much stake as anyone in weighing a drug's side effects against its advantages. Last week the Upjohn Co. withdrew Monase. a "psychic energizer,"after reporting to FDA that widespread use since June 1961 had produced seven cases of aplastic anemia, four of them fatal-though the drug was tested in 3,500 patients, with no sign of damage to their blood-cell mechanisms, before it was marketed...